Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
NCT01828008 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2013-04-10
Summary
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Conditions
Sponsors & Collaborators
-
Han weidong
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-30
- Primary Completion
- 2015-05-31
- Completion
- 2015-05-31
More Related Trials
-
Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)
NCT05115409 ·Status: UNKNOWN ·Phase: PHASE2
-
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT04074330 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
NCT05040906 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003849 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
NCT00022971 ·Status: TERMINATED ·Phase: PHASE1
-
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
NCT04491721 ·Status: ENROLLING_BY_INVITATION
-
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600 ·Status: COMPLETED
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00003150 ·Status: COMPLETED ·Phase: PHASE3
-
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
NCT01685008 ·Status: COMPLETED ·Phase: PHASE2
-
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT03485118 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma
NCT00556699 ·Status: COMPLETED ·Phase: PHASE1
-
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
NCT04028440 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00278408 ·Status: COMPLETED ·Phase: PHASE3
-
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
NCT03456466 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
NCT00285428 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant
NCT02109809 ·Status: TERMINATED ·Phase: NA
-
Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
NCT03790891 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
NCT05506410 ·Status: RECRUITING
-
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
NCT00064116 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
NCT01939730 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
NCT00429065 ·Status: UNKNOWN
-
Combination of Rituximab and NK Immunotherapy for B Lymphoma
NCT02843061 ·Status: COMPLETED ·Phase: PHASE1/PHASE2